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The ADAR RNA-editing enzymes deaminate adeno-
sine bases to inosines in cellular RNAs. Aberrant
interferon expression occurs in patients in whom
ADAR1 mutations cause Aicardi-Goutie`res syn-
drome (AGS) or dystonia arising from striatal neuro-
degeneration. Adar1 mutant mouse embryos show
aberrant interferon induction and die by embryonic
day E12.5. We demonstrate that Adar1 embryonic
lethality is rescued to live birth inAdar1;Mavs double
mutants in which the antiviral interferon induction
response to cytoplasmic double-stranded RNA
(dsRNA) is prevented. Aberrant immune responses
in Adar1 mutant mouse embryo fibroblasts are
dramatically reduced by restoring the expression of
editing-active cytoplasmic ADARs. We propose
that inosine in cellular RNA inhibits antiviral inflam-
matory and interferon responses by altering RLR
interactions. Transfecting dsRNA oligonucleotides
containing inosine-uracil base pairs into Adar1
mutant mouse embryo fibroblasts reduces the aber-
rant innate immune response. ADAR1 mutations
causing AGS affect the activity of the interferon-
inducible cytoplasmic isoform more severely than
the nuclear isoform.
INTRODUCTION
In vertebrates, viral double-stranded RNAs (dsRNAs) in the cyto-
plasm bind and activate RIG-I (retinoic acid-inducible gene I)-like
cytoplasmic viral sensor proteins (RLRs) (for review, see Takeu-
chi and Akira, 2010). The known features that these sensors use
to discriminate virus and pathogen RNAs from host cytoplasmic
RNAs include the presence of dsRNA ends and 50 triphosphates.1482 Cell Reports 9, 1482–1494, November 20, 2014 ª2014 The AutRLRs translocate on dsRNA, and some RLRs may scan dsRNA
to help distinguish between host and virus molecules. Cyto-
plasmic viral RNAs usually lack modifications, because most
viruses do not encodemodifying enzymes. It has been proposed
that nucleic acid modifications of cellular RNAs help innate
immune sensors to avoid aberrant activation by host nucleic
acids (Gehrig et al., 2012; Kariko´ et al., 2005; Vitali and Scadden,
2010). Consistent with this idea, transfection of in-vitro-tran-
scribed RNA into cultured cells generates an innate immune
response. However, if the RNA is synthesized to contain naturally
occurring modified bases, then the modified RNA does not
cause innate immune induction (Kariko´ et al., 2005; Warren
et al., 2010).
Suppression of responses of innate immune RNA sensors
by modifications normally present in host RNAs could act as
thresholding mechanisms to help prevent aberrant responses.
Response thresholding mechanisms may be required because
some cellular RNAs do contain RNA duplexes or have 50 triphos-
phates. RNA duplexes in host RNAs are particularly hazardous;
some Alu hairpins are still present in 30 UTRs of mature mRNAs
in the cytoplasm (Capshew et al., 2012). Transcription also
occurs over most of the human genome, which inevitably
generates further dsRNA that may reach the cytoplasm (Kapra-
nov et al., 2007). The RIG-I and MDA5 (melanoma differentiation
associated gene 5, IFIH1; interferon induced with helicase
C domain 1) sensors are activated by binding RNA duplexes
and signal through the MAVS (mitochondrial antiviral signaling)
adaptor protein to activate NFkB, IRF3/7, and AP1. This acti-
vates transcription of genes encoding type I interferon (IFN)
and proinflammatory cytokines. Secreted type I IFN binds to
cell-surface type I IFN receptors to amplify and spread the anti-
viral response, inducing transcription of a large set of antiviral,
IFN-stimulated genes (ISGs). Aberrant or chronic activation of
IFN-stimulated defense processes is very damaging to the host.
Experiments in cultured cells do not test the overall impor-
tance of RNA modification for restraining innate immune
responses in whole-model organisms or in human diseases.hors
However, recent findings on human gene mutations causing
autoimmune diseases are consistent with possible significant
roles for RNA modifications in autoimmune diseases. For
instance, mutations in the ADAR1 gene encoding one RNA-
editing adenosine deaminase acting on RNA cause Aicardi-
Goutie`res syndrome (AGS) (Rice et al., 2012). AGS is a fatal
childhood encephalopathy with aberrant IFN expression and
symptoms resembling those caused by congenital virus infec-
tion. Similar rare mutations in ADAR1 also cause dystonia
due to bilateral striatal neurodegeneration associated with IFN
overproduction (Livingston et al., 2014). Over 100 mutations
in ADAR1 have been identified in East-Asian patients with
dyschromatosis symmetrica hereditaria (DSH), a mild genoder-
matosis with mostly unknown IFN status, in which the dominant
phenotype appears to be often due to ADAR1 haploinsufficiency
(Liu et al., 2006).
ADARs catalyze the deamination of adenosine to inosine,
which is the most common base modification known to occur
in mammalian RNA (Gerber and Keller, 2001). Inosine is readily
detected in transcriptome sequence data because inosine
prefers to base pair with cytosine, leading to replacement of
genome-encoded adenosine (A) by guanosine (G) at edited po-
sitions in cDNA sequences. ADARs edit particular adenosine
residues at specific positions in short RNA duplexes in protein-
coding transcripts, and they also edit numerous adenosines
promiscuously in longer dsRNAs (for review, see Heale and
O’Connell, 2009). Site-specific RNA-editing events in transcript
open reading frames that generate new isoforms of encoded
proteins represent the best-understood mechanism of ADAR
action. Vertebrates have two enzymatically active ADAR pro-
teins: ADAR1 (ADAR) and ADAR2 (ADARB1). Editing of the crit-
ical Q/R site in the transcript encoding the key AMPA receptor
subunit is performed by ADAR2. Mutant Adar2 mice die from
seizures within 3 weeks of birth, and seizures and death are
prevented by knocking in an editing-equivalent A to G mutation
in the AMPA receptor subunit gene (Higuchi et al., 2000).
Adar1 mutant mice die by embryonic day E12.5 with massive
overproduction of IFN, loss of embryonic liver hematopoietic
cells, liver disintegration, and widespread apoptosis (Hartner
et al., 2004; Wang et al., 2004). Cultured Adar1 mutant embry-
onic fibroblasts are also highly sensitive to stress-induced
apoptosis (Hartner et al., 2004; Wang et al., 2004). For many
years, research has focused on identifying a key ADAR1 target
transcript analogous to the AMPA receptor transcript. However,
among the approximately 60 known editing events that recode
open reading frames, many of the key events are catalyzed
primarily by ADAR2, and none appears likely to account for
the Adar1 mutant embryonic lethal phenotype. However, only
0.4% of human A-to-I editing occurs within protein-coding
sequences (Peng et al., 2012); the vast majority of known A-to-
I-editing sites, now estimated at over 100 million in the human
genome (Bazak et al., 2013), have been found in RNA duplex-
forming pairs of Alu elements embedded in inverted orientations
near each other in introns and 30 UTR regions of transcripts.
Editing of cellular dsRNA leads to formation of I-U wobble
base pairs that cause bending and alter the properties of the
dsRNA helix; multiple sequential I-U base pairs and high levels
of promiscuous editing destabilize dsRNA. Editing of endoge-Cell Renous RNA duplexes may lower the risk that they aberrantly
induce innate immune responses. The constitutive ADARp110
isoform is a shuttling protein that accumulates mainly in the
nucleus and edits dsRNA before nuclear export (Desterro
et al., 2003). The N-terminally extended ADARp150 isoform,
expressed from a late IFN-inducible promoter, is predominantly
cytoplasmic and has been shown to edit viral RNAs (Samuel,
2011). Transfected dsRNA oligonucleotides containing inosine-
uracil (I:U) base pairs have been shown to bind to RLRs compet-
itively with poly I:C and to suppress activation of innate immune
responses (Vitali and Scadden, 2010).
We reveal that loss of ADAR1 RNA-editing activity and the
resulting loss of inosine bases in RNA are critical in producing
aberrant RLR-mediated innate immune responses in Adar1
mutant mice and cultured mouse cells. We characterize the
immune response-blocking actions of human ADAR1 protein in
Adar1 mutant mouse cells and show that most AGS-associated
ADAR1 mutant proteins have impaired RNA-editing activity.
RESULTS
IFN Receptor Mutation Partially Rescues Mouse Adar1
Mutant Embryonic Lethality, whereas Mavs Mutation
Rescues to Live Births
We wished to investigate whether aberrant immune responses
are critical to the Adar1 mutant embryonic lethal phenotype in
mice. Preventing type I IFN signaling is sufficient to fully rescue
embryonic lethality in embryos mutant for DNaseII (Yoshida
et al., 2005) that also die with type I IFN overproduction. We
constructed mouse strains that generate Adar1; Ifnar1 (IFN-a
and -b receptor 1) double-mutant embryos in crosses. No live
Adar1/; Ifnar1/ progeny were obtained (Table S1). Staged
embryo collections from crosses of Adar1+/; Ifnar1/ parents
suggest that the embryonic lifespan of the double homozygous
Adar1/; Ifnar1/ embryos was extended due to Ifnar1/
(Table 1; Figure 1); the mixed C57Bl6/129 strain background
in these crosses had little effect (Table S1). Responses to
secreted type I IFN are not the main reason for Adar1 mutant
embryonic lethality.
Although embryonic death is delayed, histological analysis of
the Adar1; Ifnar1 embryos revealed that the rescued embryos
die with defects similar to those seen in the Adar1 mutant (Fig-
ure S1A). Rescue is incomplete and variable at E14.5–E15.5 (Fig-
ures 1A–1F), and some embryos still have major defects in liver
structure with apoptotic nuclei both in hepatocytes and hemato-
poietic cells (Figures 1E–1H). Liver, heart, and lungs are under-
developed in Adar1; Ifnar1 embryos compared to wild-type;
there are fewer densely staining hematopoietic cells in the
Adar1; Ifnar1 liver, and there is an apparent lack of peripheral
blood in or around any of the organs (Figure 1). In the E15.5
Adar1; Ifnar1 liver, 58% of the erythrocytes are still nucleated,
versus5% in thewild-type (Figure S1B). A highly similar pheno-
type was observed in Adar1/; Stat1/ embryos, with hemato-
poietic defects and subsequent lethality occurring around E15.5
(Figure S1C; Table S1). Stat1 is a key mediator of systemic IFN
responses (Stark and Darnell, 2012). Embryonic lethality occurs
earlier in Adar1 mutant than in the DNaseII mutant and does not
depend on the amplifying effect of high type 1 IFN secretion.ports 9, 1482–1494, November 20, 2014 ª2014 The Authors 1483
Table 1. Survival of Mouse Embryos with Different Adar1
Genotypes from Crosses between Adar1+/; Ifnar1/ (C57Bl6N/
129) or Adar1+/; Mavs/ (C57Bl6N/J) Parents
Day Litters Embryos Adar1+/+ Adar1+/ Adar1/
Exp.
Adar1/
Parents crossed; Adar1+/; Ifnar1/
E 11.5 2 14 4 7 3 3.50
E 12.5 2 13 6 7 0 3.25
E 13.5 4 22 4 14 4 5.50
E 14.5 4 28 8 15 5 7.00
E 15.5 5 33 16 16 1 8.25
E 16.5 2 9 0 6 3 2.25
E 17.5 2 10 5 5 0 2.50
Total 129 43 70 16
Parents crossed; Adar1+/; Mavs/
E 11.5 7 59 17 32 10 14.75
E 12.5 2 15 4 7 4 3.75
E 13.5 2 19 5 10 4 4.75
E 14.5 2 11 3 7 1 2.75
E 15.5 4 29 8 15 6 7.25
P 0.5 7 60 17 35 8 15.00
Total 193 54 106 33Because Adar1; Ifnar1 double-mutant embryos do survive for
3–4 additional days, this suggested that rescue of Adar1mutant
embryonic lethality might be achieved with a mutation giving a
more potent, cell autonomous block to aberrant immune antiviral
activation, IFN production, and apoptosis. If cytoplasmic dsRNA
in the Adar1 mutant triggers an aberrant antiviral response by
activating RLRs, then the key adaptor protein in that signaling
pathway is the mitochondrial antiviral signaling protein MAVS.
To investigate the effect of blocking signaling from RLRs,
we generated strains that produce Adar1/; Mavs/ double-
mutant embryos in crosses. The Adar1; Mavs double-mutant
embryos have a significantly extended survival up to live birth
of pups (Table 1; Figure 2A). Histological sections through a
newborn Adar1; Mavs pup show apparently normal liver, heart,
and other internal organs (Figure 2A). The Adar1; Mavs double-
mutant pups are able to feed, but they die within a day of birth.
Preliminary data suggest that the newborn pups still show
heightened IFN and interleukin 1 (IL-1) expression in blood
(data not shown). This rescue shows that Adar1 mutant embry-
onic lethality is largely due to aberrant RLR/MAVS pathway
signaling triggering apoptosis.
To investigate innate immune responses in more detail, six
primary mouse embryonic fibroblast (MEF) cultures were estab-
lished representing all possible Adar1 genotypes inMavsmutant
or wild-type genetic backgrounds. Constitutive and polyriboino-
sinic:polyribocytidylic acid (poly I:C)-induced levels of IFN-a and
interleukin-6 (IL-6) proteins were measured in early-passage
MEF culture supernatants by ELISA. Adar1/; Mavs+/+ MEFs
show a detectably elevated basal level of IFN-a and respond
to poly I:C by producing higher levels of both IFN-a and IL-6
than the wild-type (Adar1+/+; Mavs+/+) MEFs. Surprisingly, het-
erozygous Adar1-/+ MEFs behave somewhat like homozygous1484 Cell Reports 9, 1482–1494, November 20, 2014 ª2014 The AutAdar1/mutant MEFs and respond vigorously to poly I:C treat-
ment with heightened expression of both IFN-a and IL-6. This
suggests that prevention of aberrant immune responses in
Adar1-/+ MEFs is very sensitive to levels of ADAR1, consistent
with evidence of ADAR1 haploinsufficiency in DSH patients
(Liu et al., 2006). Confirming that Mavs mutation blocks the
aberrant innate immune responses caused by the Adar1 muta-
tion, aberrant expression of type I IFN and proinflammatory
cytokines observed in Adar1/;Mavs+/+ MEFs is prevented in
the Adar1/; Mavs/ double-mutant MEFs; these MEFs also
do not induce type I IFN or IL-6 in response to poly I:C treatment
(Figure 2B).
Transcriptional Alterations in Adar1 Mutant
Embryos Are Primarily Consequences
of Aberrant Immune Induction
To investigate whether there is an altered transcriptional profile
in Adar1 mutant embryos quantitative RT-PCR (qRT-PCR) ana-
lyses were performed to determine the expression levels of 12
interferon-stimulated gene (ISG), transcripts in total RNA from
E11.5 whole embryos. Some ISG transcripts are highly elevated
in Adar1mutant whole embryos compared to wild-type embryos
and levels return to normal in Adar1; Mavs and Adar1; Ifnar
embryos (Figure 3A), though the Adar1; Ifnar1 double-mutant
embryo does not normalize ISG transcript levels as fully as
Adar1; Mavs. The levels of these ISG transcripts in the Mavs
and Ifnar1 mutant embryos are also somewhat different from
wild-type levels (Figure S2), and therefore the relevant back-
ground has been subtracted from the double-mutant levels (Fig-
ure 3A). The qRT-PCR data confirm the ELISA data on cultured
fibroblasts showing that the abnormal IFN responses in Adar1
mutant embryos are mediated by aberrant immune signaling
through the MAVS adaptor protein.
To characterize alterations in gene expression across the
whole transcriptome in Adar1 mutant Adar1; Mavs double-
mutant embryos, we sequenced ribosomal RNA-depleted total
RNA from whole E11.5 embryos. Overall, more transcripts
decrease in whole Adar1 embryos than increase (Figure 3B);
this may be related to losses of hematopoietic cells or to more
widespread defects consistent with apoptosis observed in
Adar1mutant embryos. We identified a set of 61 protein-coding
transcripts that are upregulated at least 3-fold in Adar1 mutant
embryos and restored to near-wild-type levels in Adar1; Mavs
embryos (Table S2). Gene Ontology term analysis on the
upregulated transcripts confirms enrichment of immune and
antiviral response transcripts (Table S2). To confirm the
increased expression of immune gene transcripts in the Adar1
mutant, qRT-PCR expression analyses were performed with
total RNA from E11.5 whole embryos. Changes in proinflamma-
tory cytokine transcript expression in Adar1; Ifnar1 and Adar1;
Mavs embryos were calculated relative those in Ifnar1 and
Mavs mutants, which were again slightly different from wild-
type levels (Figure S2). Consistent with the sequencing data,
levels of certain ISGs and proinflammatory cytokines were highly
increased in the Adar1mutant compared with wild-type (Figures
3A and 3B).
Altered expression levels of immune gene transcripts in the
Adar1 mutant embryo are restored close to wild-type levels inhors
Figure 1. Partial Rescue of Adar1 Mutant
Embryo Viability and Liver Integrity in
Adar1; Ifnar1 Double Mutant
(A and B) Whole embryos and corresponding liver
sections of wild-type (A) and Adar1 mutant (B)
mice at E11.5.
(C–F) Whole embryos and corresponding liver
sections of Adar1; Ifnar1 (C and E) and Adar1;
Ifnar1 (D and F) mice at E14.5 (C and D) and E15.5
(E and F).
(G and H) Sectioned whole embryos of Adar1+/+;
Ifnar1/ (G) and Adar1/; Ifnar1/ (H) mice at
E15.5. Fetal livers outlined by red boxes.
Scale bars, liver sections (A–F), 25 mm; all others,
1 mm.both Adar1; Ifnar1 and Adar1; Mavs double-mutant embryos.
The increase in the expression of the transcription factor Stat1
is very striking in the Adar1 embryo at E11.5 and the Stat1
transcript is reduced in both Adar1; Ifnar1 and Adar1;Mavs dou-
ble-mutant embryos. STAT1 protein is critical to the cellular
response to extracellular IFN (for review, see Stark and Darnell,
2012); however, consistent with the similarly limited effect of
the Ifnar1 mutation, generating an Adar1; Stat1 double mutant
also does not rescue Adar1 mutant embryonic lethality fully
(Figure S1C). The stronger rescue of embryonic lethality by
Mavs mutation may not be due mainly to stronger effects on
transcription, but rather the Mavs mutation may also block
apoptosis or other nontranscriptional effects of aberrant RLR
signaling. Together both the qRT-PCR and ELISA data confirm
that the abnormal responses in Adar1 mutant embryos are
mediated by immune signaling through MAVS.
To examine transcription in more detail in embryonic hemato-
poietic cells, we sequenced ribosomal RNA-depleted total
RNA from E15.5 embryonic livers of Adar1; Mavs and Mavs
sibling embryos; liver is the main site of hematopoiesis at this
stage. Adar1mutant embryos die by E12.5 when embryonic liverCell Reports 9, 1482–1494, Nois still small.Adar1;MavsE15.5 fetal livers
appear normal and comparisons of RNA
sequencing (RNA-seq) data from Adar1;
Mavs and Mavs livers could not identify
any protein-coding transcripts expressed
at significantly differing levels. The lack
of aberrant transcription in Adar1; Mavs
livers shows that all observed alterations
in levels of protein-coding transcripts
in the Adar1 mutant are effects of aber-
rant RLR signaling and interferon pro-
duction. Transcriptional alterations are
not caused directly by loss of ADAR1
protein per se.
It has been proposed that RNA editing
could increase turnover of edited dsRNA
due to cleavage by an inosine-specific
ribonuclease, but the physiological effec-
tiveness of this turnover process is not
known (Scadden, 2005). If increased
levels of repetitive transcripts withdsRNA-forming potential do arise in the Adar1 mutant, these
might cause the aberrant antiviral response. If repetitive tran-
scripts increase as a direct result of the absence of Adar1,
the aberrant repetitive transcript levels should be detected
also in the Adar1; Mavs double mutant. To assess expression
of transcripts likely to form dsRNA, a detailed analysis of repet-
itive sequence expression in Adar1; Mavs and Mavs E15.5
liver total RNA-seq data was performed (Figure 4). Increased
expression of individual members of ERV and IAP subfamilies
was observed (Table S3), and qRT-PCR analyses confirmed
increased expression of MMERVK10C transcripts (Figure 4E).
Overall, however, changes in repetitive transcripts parallel those
seen for protein-coding transcript; i.e., levels of most repetitive
elements did not change between Adar1; Mavs and Mavs. This
suggests that a general dramatic increase in levels of repetitive
transcripts due to slowed turnover is not the initiating event
in the aberrant immune response in Adar1 mutants. Changes
in some individual repetitive transcripts could contribute to
initiating aberrant immune responses in the Adar1 mutant, but
the reduction in inosine levels within cellular dsRNA is perhaps
more critical.vember 20, 2014 ª2014 The Authors 1485
Figure 2. Rescue of Adar1 Mutant Pheno-
types in Adar1; Mavs Double-Mutant Mice
and MEF Cultures
(A) Gross visceral anatomy of Adar1/; Mavs/
newborn mice. (i) Appearance of pups at P0.5.
(ii–vi) Sections showing general visceral anatomy
(ii) with further detail of heart (iii), liver (iv), intestines
(v), and rectum (vi). Scale bars in (i) and (ii), 3 mm
and (iii)–(vi), 400 mm.
(B) ELISA showing mean levels of IFN-a and IL-6
in cell-culture supernatants of Adar1+/+, Adar1+/,
and Adar1/ MEFs with Mavs+/+ or Mavs/
backgrounds following transfection with poly(I:C)
(1 mg/ml; +) or water (). The units on the y axis
are expressed per 10,000 cells. Error bars, SD.Restoring Expression of Editing-Competent ADARs
Prevents Aberrant Innate Immune Responses in Adar1
Mutant Mouse Fibroblasts
To determine whether the aberrant antiviral response in Adar1
mutant cells is due to reduced inosine modification in intracel-
lular RNAs, we established MEF cell cultures from Adar1; p53
double-mutant embryos. Adar1 MEFs could not be cultured
long term due to cell death (Figure S3), and Adar1; Mavs dou-1486 Cell Reports 9, 1482–1494, November 20, 2014 ª2014 The Authorsble-mutant MEFs are not useful because
the aberrant innate immune response
is blocked. When compared with p53
mutant MEFs, elevated expression of
ISGs is observed in Adar1; p53 MEFs
when cultures are stressed by nutrient
starvation (Figure 5A); without stress,
ISG expression is very low in Adar1; p53
MEFs. We chose the p53 mutant back-
ground because this prevents cell death
associated with a range or other muta-
tions (Dittmer et al., 1993). The reduction
in aberrant ISG expression in Adar1; p53
versus Adar1 MEFs is consistent with
the idea that preventing cell death is
also an important feature of the Mavs
mutant rescue.
To test for rescue of Adar1 mutant
phenotypes by ADAR protein variants,
we next established stable Adar1; p53
MEF lines expressing wild-type or
mutant human ADAR1 proteins from
stably integrated PiggyBac constructs
that we previously characterized (Heale
et al., 2009). The Adar1; p53 PiggyBac
MEFs were starved for 72 hr to stress
the cells, total RNA was isolated and
qRT-PCR was performed to measure
ISG transcript levels. Expression levels
of ISG transcripts were normal in p53
mutant cells and highly elevated in
Adar1; p53 cells (Figure 5A). When either
the predominantly nuclear ADAR1 p110isoform or the IFN-inducible mainly cytoplasmic ADAR1p150
isoform were expressed, ISG transcripts were significantly
reduced (Figure 5A). Expressing the ADAR1p150 (E912A)
mutant that inactivates the deaminase catalytic site gave the
least effective reduction in ISG levels. These data indicate
that robust suppression of ISG transcription requires a catalyt-
ically active ADAR capable of deaminating adenosine to inosine
into RNA.
Figure 3. Rescue of Adar1Mutant Embryo Aberrant Proinflammatory Cytokine Expression in Adar1; Ifnar1 and Adar1;Mavs Double-Mutant
Embryos
(A) Expression levels for an array of 12 ISGs measured in E11.5 whole embryos. For each gene, Adar1/, Adar1/; Ifnar1/, and Adar1/; Mavs values are
expressed relative to wild-type, Ifnar1, orMavs background levels, respectively (one on y axis, dashed lines). Error bars, SEM. *p% 0.05; **p < 0.01; ***p < 0.001
versus wild-type; yyp < 0.01; yyyp < 0.001 versus Adar1; zzzp < 0.001 versus Adar1/; Ifnar1/.
(B) Heatmap showing expression levels for an array of 96 proinflammatory cytokine and control transcripts measured in E11.5 whole embryos. For each gene,
Adar1/, Adar1/; Ifnar1/, and Adar1/; Mavs/ values are expressed relative to wild-type, Ifnar1/, or Mavs/ background levels, respectively, which
are all zero following log10-transformation and hence are not shown (white in color).Expressing human ADAR2DN, a nuclear localization mutant
of ADAR2 that aberrantly accumulates in the cytoplasm
(Wong et al., 2003), in Adar1; p53 MEFs also significantly
reduced expression of the ISGs (Figure 5A). This suggests
that restoring RNA-editing activity in the cytoplasm is particu-
larly important. MEF cells already express endogenous, active,
ADAR2 in the nucleus, and site-specific editing of protein-
coding transcripts usually involves transient exon-intron RNA
duplexes formed before splicing. ADAR2 proteins have dif-
ferent specific site preferences from ADAR1 proteins (Keegan
et al., 2011). The ADAR2DN is more likely to rescue nonspe-
cific, promiscuous editing events lost in the Adar1 mutant
than it is to edit some transcript containing a highly ADAR1-
specific site. The sufficiency of either catalytically active ADAR
for strong rescue is consistent with the idea that loss of pro-
miscuous editing in intracellular dsRNA is critical to the Adar1
mutant phenotype.Cell ReTransfecting dsRNA Containing I-U Base Pairs Prevents
Aberrant Antiviral Responses in Adar1 Mutant Mouse
Fibroblasts
If cellular dsRNA lacking inosine in Adar1 mutant cells is suffi-
cient to induce an aberrant innate immune response, then
isolating RNA from Adar1 mutant cells and transfecting it into
wild-type cells might replicate this effect. Therefore, we ex-
tracted total RNA from livers of Adar1; Mavs E15.5 embryos
and transfected this into RIG-I reporter cells but could not detect
any difference between the responses induced by Adar1; Mavs
and wild-type RNA samples. Because the majority of a total
RNA sample is rRNA or tRNAs, this experiment may not mimic
in vivo conditions. We decided to perform instead the converse
experiment, which was to determine if inosine-containing RNAs
interfere with immune induction by transfected RNA.
To elucidate if transfecting dsRNA oligonucleotides containing
inosine-uracil base pairs suppress aberrant ISG expression inports 9, 1482–1494, November 20, 2014 ª2014 The Authors 1487
Figure 4. Repetitive Element Expression in Adar1; Mavs Embryonic Mouse Liver
(A–C) Expression profiles of repetitive element classes (A), retrotransposon subfamilies (B), and specific LTR retrotransposon populations (C) in Adar1/;
Mavs/ E15.5 liver total RNA relative to Mavs/ (zero on x axis).
(D) Schematic of the prototypical mouse RLTR10C-flanked MMERVK10C retrotransposon (generated using Jurka et al., 2005). Positions and lengths of the gag,
pro, pol, and env genes are shown. Black bars indicate qRT-PCR products (i–xi) generated using specific primer pairs (Table S4).
(E) Expression levels of RLTR10C-flankedMMERVK10C retrotransposon regions shown in (D) inAdar1/;Mavs /E15.5 livers relative toMavs/ (one on y axis,
dashed line).
Error bars, SEM. *p% 0.05; **p% 0.01; ***p% 0.001 versus Mavs for each region.Adar1 mutant phenotype, we established a test system using
Adar1; p53 MEFs. To partially induce innate immune responses
in Adar1; p53MEFs, we transfected these cells with levels of an1488 Cell Reports 9, 1482–1494, November 20, 2014 ª2014 The Autin-vitro-transcribed Fluc mRNA that has been shown previously
to induce a modest innate immune response in HeLa cells
(Vitali and Scadden, 2010). Transfecting similar concentrationshors
of FlucRNA into the hypersensitive Adar1; p53MEF cells caused
a dramatic increase in expression of ISG transcripts (Figure 5B),
as in the case of serum starvation (Figure 5A). This strong
response of Adar1; p53 MEFs to transfected RNA is likely to
reflect the aberrant immune induction due to the Adar1mutation.
Transfecting dsRNA oligos alone into Adar1; p53 MEFs has
very little effect on immune induction at the concentrations
used (Figure 5C). dsRNA oligonucleotide (C-dsRNA) or IU-
dsRNA that contained four inosine-uracil base pairs were then
cotransfected with 500 ng FlucRNA to look for specific inhibitory
effects of IU-dsRNA oligonucleotides on ISG transcript induction
(Figure 5C). IU-dsRNAs further reduce ISG transcript expression
below reductions caused by control C-dsRNAs (Figure 5D).
These reductions in ISG transcript levels were maintained for
24 hr with the IU-dsRNA, whereas the C-dsRNA was unable to
reduce the ISG response at this time point (data not shown).
The background inhibitory effect of the control C-dsRNA oligo-
nucleotide in these experiments could arise if the 20-mer dsRNA
oligonucleotides bind only one RLR molecule each, thus
impeding oligomerization of RLR CARD domains (Peisley et al.,
2014). It is clear that transfection of I-U dsRNA specifically in-
hibits aberrant immune induction further. Both this specific effect
of I-U base pairs and the general suppressive effect of 20-mer
dsRNA oligonucleotides indicate that aberrant RNA complexes
formed by RLRs are central to the Adar1 mutant phenotype.
Mutations in Human ADAR1 Associated with AGS
Have More Severe Effects on the IFN-Inducible
Isoform of ADAR1
Most of the mutations in ADAR1 occurring in patients with AGS
change residues on the surface of the catalytic domain at the C
terminus of the protein (Figure 6), close to where dsRNA is pre-
dicted tobind. Previously,we tested the effects of theseAGSmu-
tations on enzymatic activity in ADAR1p110 (Rice et al., 2012).
Constructs expressing ADAR1p110 were transiently cotrans-
fected into HEK293 cells with a construct expressing a known
editing substrate for ADAR1 and editing activity was measured.
Surprisingly,most of theAGSmutant proteins,with the exception
of the ADAR1 G1007R mutation, still exhibited robust editing
activity, though with statistically significant reductions.
We now tested the effects of the same AGS mutations in
ADAR1p150 in a similar manner (Figure 6A). Each of the AGS
mutations causes a significant decrease in editing activity of
ADAR1p150 that is greater than the effect of the same mutation
in the ADAR1p110 isoform. This large difference betweenmutant
effects in the two isoforms was not anticipated because the AGS
mutations are predominantly in the C-terminal domains shared
by the two isoforms. We provide a report of mutations in
ADAR1 that have different effects on the two isoforms, revealing
a significant separation of roles for the two isoforms. These find-
ings also imply that the effects of AGS mutations in ADAR1 are
mediated particularly through ADAR1p150 and primarily involve
reductions in RNA-editing activity. Loss of the IFN-inducible
cytoplasmic ADAR1 isoform may be important in AGS and
dystonia patients. Clinical observations have suggested that
symptoms may develop following an infection when type I
IFN expression should have led to later expression of active
ADAR1p150 (Livingston et al., 2014)Cell ReADAR1mutant proteins found inAGSpatientswere also tested
for effects on RNA-editing activity in HEK293 cells when ex-
pressed in combinations matching those observed in the AGS
patient cohort (Figure 6B). Evidence for interactions between
different AGSmutations in the sameADAR1 protein and for inter-
actions between different ADAR1 mutant proteins in heterozy-
goteswas obtained. For instance, we found that theADAR1p150
P193A mutant exhibits a significant decrease in editing activity
(Figure 6A). TheP193Amutation is expressed only in theN-termi-
nally extended ADAR1p150 isoform and increases the effect of
other AGS mutations in the same protein (Figure 6B). The crystal
structure of the ADAR1 N-terminal Z-alpha domain complex with
Z-RNA has been solved, and the P193A mutation is predicted
to change a highly conserved amino acid involved in nucleic
acid contact (Schade et al., 1999). This variant is enriched in
the AGS cohort but is also present in 41 of 6,553 control patients
in the Exome Variant Server database. An instance of strong
interaction between different ADAR1 protein variants in AGS
heterozygote patients is seen with the ADAR1p110 G1007R
mutant that binds dsRNA but is catalytically inactive and which
exerts a dominant-negative effect on editing by ADAR1p110
wild-type protein (Rice et al., 2012) (Figure 6B).
DISCUSSION
This study elucidates a key conserved role for ADARs in prevent-
ing aberrant IFN responses by cytoplasmic antiviral RLR innate
immune RNA sensors. Mouse Adar1mutant embryos die by em-
bryonic day E12.5 with aberrant IFN expression, failure of hema-
topoiesis, and degeneration of the embryonic liver (Hartner et al.,
2004, 2009; Wang et al., 2004). We obtained partial rescues of
Adar1 mutant embryonic lethality by combination with Ifnar1 or
Stat1 mutations and a much more substantial rescue to live
birth by combination with a Mavs mutation. The Mavs rescue,
in particular, indicates that the Adar1 embryonic lethal mutant
phenotype is largely due to an aberrant antiviral response.
Some mutations affecting RLRs have phenotypes similar to
Adar1 mutants, for example, a mutation in the mouse Ifih1
gene encoding MDA5 that causes constitutive IFN signaling (Fu-
nabiki et al., 2014), giving rise to a Lupus-like autoimmune disor-
der. Mutations in Mavs but not Ifnar1 also rescued the aberrant
immune response in those Ifih1 mice. In addition, with striking
similarity to ADAR1, mutations in human IFIH1 also cause AGS
(Rice et al., 2014). Our preliminary data indicate, however, that
combining Ifih1 with Adar1 does not rescue the lethality of the
Adar1 mutant mouse embryo (data not shown), suggesting that
MDA5 is not the sole mediator of the Adar1 mutant phenotype.
Loss of the late IFN-inducible cytoplasmic ADAR1 p150
isoform, in particular, may be critical to the Adar1mutant pheno-
type. This isoform interacts in a complex way with viruses and
may participate in the resolution phase of the IFN response by
editing residual viral RNAs (Ward et al., 2011). ADARs have
been reported as being ‘‘proviral’’ because ADARs facilitate
replication of viruses in cultured cells (Samuel, 2011). However,
proviral effects are unusual among proteins induced by IFN,
and these experiments in cell cultures may be somewhat
misleading. Studies on Adar1 mutant mice lacking only the
ADAR1 p150 isoform instead suggest an overall negative effectports 9, 1482–1494, November 20, 2014 ª2014 The Authors 1489
(legend on next page)
1490 Cell Reports 9, 1482–1494, November 20, 2014 ª2014 The Authors
Figure 6. Mutations in ADAR1 that Cause Aicardi-Goutie`res Syndrome Affect RNA-Editing Activity
The first letter denotes the original amino acid and the second letter the mutation; the number is the position of the amino acid in the p150 isoform.
(A) Editing activity of each ADAR1 AGS mutant in either the p110 or p150 isoform expressed in HEK293T cells relative to wild-type p110 or p150, respectively
(100% on y axis, dashed line). Error bars, SEM. *p% 0.05; **p < 0.01; ***p < 0.001.
(B) Editing activity of the ADAR1 mutant combinations found in an AGS patient cohort in the p150 isoform expressed in HEK293T cells relative to wild-type
p150 (100% on y axis, dashed line). Error bars, SEM. ***p < 0.001 versus wild-type p150.
(C) A diagram of ADAR1 illustrating where the AGS mutations occur in the protein.of ADAR1 p150 on measles virus propagation, illustrating the
importance of whole-animal studies (Ward et al., 2011). Hepatitis
C virus encodes a protease that cleaves MAVS, and it would be
interesting to determine whether this virus or protease rescue
aspects of Adar1 mutant phenotypes.
We show that signaling from antiviral innate immune sensors
through MAVS is inhibited by dsRNA oligonucleotides contain-
ing inosine-uracil base pairs. Transfection of I-U dsRNA corre-
sponding to an ADAR1-edited section of an artificial dsRNA
substrate into Adar1 mutant MEFs suppresses the aberrantFigure 5. Aberrant Innate Immune Responses in Adar1/; p53/ Doub
IU-dsRNA
(A) Expression levels for an array of five ISGs measured in nutrient-starved (72 h
ADAR proteins. For each gene, values are expressed relative to p53/ (one on y
SEM. *p < 0.05; **p < 0.01; ***p < 0.001 versus p53/; yyp < 0.01; yyyp < 0.001
(B) Expression levels for an array of 5 ISGs following transfection of Adar1/; p5
are expressed relative to mock transfection (0 ng) at 12 hr and normalized to the
(C) Expression levels for an array of five ISGs following transfection of Adar1/; p
each gene, values are expressed relative to that seen after 6 hr in cells transfecte
to the housekeeping gene ActB. Error bars, SEM. *p < 0.05; ***p < 0.001.
(D) Expression levels for an array of five ISGs and one housekeeping gene follo
(control), with either control dsRNA (C-dsRNA) or IU-dsRNA. For each gene, value
dsRNA (C-dsRNA) (one on y axis, dashed lines) and normalized to the housekee
Error bars, SEM. *p < 0.05; **p < 0.01; ***p < 0.001 versus control.
Cell Reantiviral response. The data suggest that the aberrant antiviral
response in the Adar1 mutant results from loss of inosine in
cytoplasmic dsRNA that normally inhibits antiviral sensor acti-
vation. Other examples of how changes in modification states
of RNAs determine innate immune responses come from viruses
encoding ribose 20-O-methylation enzymes that methylate viral
mRNA cap structures to match host mRNA caps so that they
avoid activating the MDA5 sensor (Zu¨st et al., 2011). Vertebrate
tRNAs also have specific modifications at certain positions in
their structures that allow innate immune sensors to discriminatele-Mutant MEFs Are Suppressed by Expression of ADAR Proteins or
r) Adar1/; p53/ MEF cultures following stable knockin of GFP (control) or
axis, dashed lines) and normalized to the housekeeping gene ActB. Error bars,
versus Adar1/; p53/.
3/ MEF cultures with 0–500 ng FlucmRNA after 12 hr. For each gene, values
housekeeping gene ActB. Error bars, SEM.
53/MEF cultures with control dsRNA (C-dsRNA) or IU-dsRNA after 12 hr. For
d with control dsRNA (C-dsRNA) (one on y axis, dashed lines) and normalized
wing transfection of Adar1/; p53/ MEF cultures with 500 ng Fluc mRNA
s are expressed relative to expression after 6 hr in cells transfected with control
ping gene ActB.
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between them and bacterial tRNAs (Gehrig et al., 2012). Modifi-
cations that occur naturally in host RNAs also prevent activation
of other innate immune sensors such as PKR and Toll sensors
(Nallagatla et al., 2008). Because transfection of I-U dsRNA
blocks the aberrant immune activation in Adar1; p53 MEFs, it
is most likely that the aberrant immune activation is due to an
endogenous dsRNA that activates RLRs. We cannot exclude
the possibility that a site-specific editing event contributes,
but, if the Adar1 mutant aberrant immune induction was due to
loss of editing in a transcript encoding an innate immune protein
or any other indirect effect, then inhibiting RLRs at the level of
RNA interaction would be unlikely to rescue.
In the case of I-U dsRNA inhibition of RLRs, the significant
effect of sequential I-U wobble base pairs bending and destabi-
lizing dsRNA (McLaughlin and Keegan, 2014) makes it possible
to envisage why the sensors are able to detect edited dsRNA
(Figure S4). I-U dsRNA binds the RLRs competitively with acti-
vating dsRNA (Vitali and Scadden, 2010), probably making
grossly similar contacts to the helicase domains and carboxy-
terminal domains. RLRs are suitable to assess dsRNA structure
because they surround the dsRNA using multiple protein do-
mains to make many contacts to both strands (Kowalinski
et al., 2011; Luo et al., 2011). The Hel2i domain, in particular,
could have a role in scanning the dsRNA minor groove to detect
I-U base pairs and other imperfections (Figures S4C and S4D),
possibly leading to alterations in dynamic RLR domain rear-
rangements required for signaling. Natural RNA duplexes formed
by repetitive elements in transcripts will usually be imperfectly
paired, and RNA editing will further reduce helical regularity. For-
mation of regular filaments by RLRs on dsRNA facilitates forma-
tion of CARD domain complexes activating MAVS signaling
(Kowalinski et al., 2011; Peisley et al., 2014). RLR signaling
may be exquisitely sensitive to mismatches and RNA-editing
events present in RNA duplexes that indicate the dsRNA is not
a direct product of virus replication.
In Adar1; p53 mutant MEFs, the catalytically inactive ADAR1
protein is the least effective at reducing elevated ISG transcripts
though it is still RNA binding competent, demonstrating that
RNA-editing activity is required. Catalytically active ADAR1 pro-
teins and even a cytoplasmically mislocalized ADAR2 mutant
protein (Wong et al., 2003) reduce the aberrantly elevated
ISG transcript levels. This emphasizes the role of RNA-editing
activity, argues against a dominant role for ADAR1-specific
protein-protein or protein-RNA interactions, and suggests that
promiscuous editing by ADARs is involved rather than a highly
ADAR1-specific editing event. No ADAR1 protein fully sup-
pressed ISG transcripts to levels observed in the p53/ mutant,
but the reintroducedADAR1proteins are not expressedunder the
control of the IFN-inducibleAdar1promoter itself. Because trans-
fection of general dsRNA oligonucleotides containing inosine-
uracil base pairs significantly reduces elevated ISG levels in
Adar1; p53MEFs, the importance of inosine in RNA in preventing
the innate immune response is supported in two distinct ways.
Several of the AGS mutations alter residues on the surface of
the deaminase domain close to where RNA is predicted to bind
(Rice et al., 2012), and it is possible that the D1113H mutation,
which affects editing activity the least, alters ADAR1 function in
other ways such as by perturbing protein and/or RNA interac-1492 Cell Reports 9, 1482–1494, November 20, 2014 ª2014 The Auttions required for suppression of innate immunity. In addition
to the catalytically active ADAR1 and ADAR2 proteins, two other
vertebrate ADARs lack catalytic deaminase activity (for review,
see Heale and O’Connell, 2009). Therefore, editing-independent
ADAR roles are maintained and could involve protein interac-
tions on dsRNA or sequestration of dsRNA.
While this manuscript was under review,Wang and colleagues
showed a substantially stronger editing-independent role of
ADAR1 in decreasing innate immune responses in HEK293
(Yang et al., 2014). We also observe some editing-independent
rescue, and we suspect that the difference is due to our use
of Adar1; p53 MEFs completely lacking ADAR1 and their use
of HEK293 cells.
We do not know why Adar1; Mavs newborn pups die within a
day of birth, but preliminary data on cytokine expression in blood
from these pups implicate some residual inflammatory effects.
Activated RLRs can bypass MAVS and induce inflammasome
responses via an alternative pathway (Lucioli et al., 2013). Cell
death is a very prominent effect in the Adar1mutant, and possible
MAVS-bypass signaling to cell death pathways in some cells
in Adar1; Mavs newborn pups also remains to be investigated.
Many important autoimmunediseasesshowtranscriptional signa-
tures of elevated ISG expression. Our findings suggest, however,
that preventing the aberrant systemic IFN response may not al-
ways be sufficient to treat these diseases. When aberrant RLR
signaling is activated, the key defects may be cell autonomous.
Correcting them will require a muchmore detailed understanding
of intracellular nucleic acid sensing. When the important cellular
modified nucleic acids that modulate innate immune responses
have been defined, theymay point theway to new therapeutic ap-
proaches to autoimmune and neurodegenerative diseases.
EXPERIMENTAL PROCEDURES
Additional methods are online in the Supplemental Information.
Mouse Genetics
Adar1D2-13 mice in the C57Bl6N background were obtained from M. Higuchi
and P. Seeburg (strain C192) (Hartner et al., 2004). These mice were crossed
to the IFN receptor subunit mutant (Ifnar1) in the 129 strain background (B&H
Animal Suppliers). Two sublines breed Adar1/+ in the Ifnar1/ background,
and crosses of these mice generate Adar1/; Ifnar1/ embryos. Two further
sublines generate heterozygous Adar1/+ animals with the mixed B6/129
strain background, and crosses of these generate control Adar1/ embryos
without the Ifnar1 mutation. The CARDIF/ (MAVS, IPS-1, or VISA) mutant
line generated by the Tschopp group in Lausanne was obtained from
Caetano Reis e Sousa in London. It is homozygous-viable null mutant in
the C57B6J background. All experiments on mice were performed in accor-
dance with Edinburgh University rules and National Guidelines on animal
experimentation.
Knockin of ADAR cDNA in MEFs
cDNAs encoding ADAR proteins were subcloned into the PiggyBac expres-
sion system (System Biosciences) and transfected into Adar1/; p53/
MEFs using LyoVec (InvivoGen). Cells were grown for 2 weeks, and those
with successful integration were isolated by fluorescence-activated cell sort-
ing (GFP positive).
Mouse Immune Array
The TaqMan Array Mouse Immune Panel (CN: 4367786; Life Technologies)
was used for quantitative gene expression analysis of the immune response
signatures in E11.5 whole embryos. Total RNA was extracted and purified,hors
and cDNA was generated as described above. The Taqman array card was
loaded with the first strand cDNA sample and Taqman Universal PCR Master
Mix II UNG (Life Technologies) according to the manufacturer’s protocol.
The amplification was performed on an upgraded version of the Applied
Biosystems 7900HT Fast Real-Time PCR System, and the analysis of the
data was performed as described above.
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